Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study
| Autor: | Wendy S. Post, Jingsha Chen, Andrew S. Levey, Kelli Goodman, Tariq Shafi, Josef Coresh, Lisa A. Ford, Yingying Sang, Michael G. Shlipak, Lesley A. Inker, Tom Greene, Regis Perichon |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Kidney Disease Time Factors 030232 urology & nephrology 030204 cardiovascular system & hematology Cardiovascular chemistry.chemical_compound 0302 clinical medicine 80 and over Medicine Renal Insufficiency Chronic kidney function African american Aged 80 and over Chromatography Liquid biology creatinine Urology & Nephrology Middle Aged Clinical Practice Nephrology Creatinine Female Glomerular Filtration Rate Adult medicine.medical_specialty Demographics Clinical Sciences Urology Renal and urogenital Renal function Proof of Concept Study GFR 03 medical and health sciences Humans Metabolomics Cystatin C Renal Insufficiency Chronic Aged Transplantation business.industry medicine.disease Metabolomic profiling Cross-Sectional Studies chemistry estimating equations biology.protein ORIGINAL ARTICLES business Biomarkers Kidney disease Chromatography Liquid Follow-Up Studies |
| Zdroj: | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association, vol 34, iss 5 |
| Popis: | BACKGROUND:Estimation of glomerular filtration rate (GFR) using estimated glomerular filtration rate creatinine (eGFRcr) is central to clinical practice but has limitations. We tested the hypothesis that serum metabolomic profiling can identify novel markers that in combination can provide more accurate GFR estimates. METHODS:We performed a cross-sectional study of 200 African American Study of Kidney Disease and Hypertension (AASK) and 265 Multi-Ethnic Study of Atherosclerosis (MESA) participants with measured GFR (mGFR). Untargeted gas chromatography/dual mass spectrometry- and liquid chromatography/dual mass spectrometry-based quantification was followed by the development of targeted assays for 15 metabolites. On the log scale, GFR was estimated from single- and multiple-metabolite panels and compared with eGFR using the Chronic Kidney Disease Epidemiology equations with creatinine and/or cystatin C using established metrics, including the proportion of errors >30% of mGFR (1-P30), before and after bias correction. RESULTS:Of untargeted metabolites in the AASK and MESA, 283 of 780 (36%) and 387 of 1447 (27%), respectively, were significantly correlated (P ≤ 0.001) with mGFR. A targeted metabolite panel eGFR developed in the AASK and validated in the MESA was more accurate (1-P30 3.7 and 1.9%, respectively) than eGFRcr [11.2 and 18.5%, respectively (P 0.05) and 9.1% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|